Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$11.75 ▲ +0.47
(+4.17%)
MKT CAP: $2.63B • VOL: 2.74M
52W L $7 52W H $20
ADMA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $510.2M | $426.5M | $258.2M |
| YoY Revenue Growth % | +19.6% | +65.2% | — |
| Gross Profit | $292.8M | $219.6M | — |
| Gross Margin % | 57.4% | 51.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $191.4M | $139.0M | $21.6M |
| Operating Margin % | 37.5% | 32.6% | 8.4% |
| Net Income (GAAP) | $146.9M | $197.7M | -$28.2M |
| EBITDA (Normalized) | $209.5M | $145.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $50.4M | $118.7M | $8.8M |
| Capital Expenditures (CapEx) | $22.6M | $8.2M | — |
| Free Cash Flow (FCF) | $27.8M | $110.4M | $8.8M |
| FCF Margin % | 5.5% | 25.9% | 3.4% |
| Return on Invested Capital (ROIC %) | 32.9% | 34.5% | — |
| Cash & Short-Term Equivalents | $87.6M | $103.1M | — |
| Total Debt (Short + Long Term) | $69.3M | $72.3M | — |
| Total Stockholders' Equity | $477.3M | $349.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ADMA.